Tumor Necrosis Factor Blocker [EPC]

831377 reported adverse events

Drugs of this class: ADALIMUMAB-ATTO INFLIXIMAB GOLIMUMAB CERTOLIZUMAB PEGOL ETANERCEPT INFLIXIMAB-AXXQ INFLIXIMAB-DYYB

These side effects are most commonly reported by patients taking drugs of the Tumor Necrosis Factor Blocker [EPC] class:

# Side effect Count
0 DRUG INEFFECTIVE 97955
1 INJECTION SITE PAIN 57976
2 ARTHRALGIA 55639
3 OFF LABEL USE 53824
4 PAIN 50399
5 RHEUMATOID ARTHRITIS 48778
6 INJECTION SITE ERYTHEMA 41598
7 FATIGUE 38045
8 CONDITION AGGRAVATED 33561
9 HEADACHE 30591
See all common reactions for Tumor Necrosis Factor Blocker [EPC]

Drugs of the Tumor Necrosis Factor Blocker [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 HUMAN ANTICHIMERIC ANTIBODY POSITIVE 292 0.9766
1 INJECTION SITE RECALL REACTION 483 0.9718
2 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 3479 0.9357
3 SWOLLEN JOINT COUNT INCREASED 835 0.8892
4 RHEUMATOID FACTOR POSITIVE 2940 0.8750
5 RED BLOOD CELL SEDIMENTATION RATE ABNORMAL 1711 0.8342
6 RHEUMATIC FEVER 1081 0.8177
7 PEMPHIGUS 6214 0.8019
8 C-REACTIVE PROTEIN ABNORMAL 2947 0.7753
9 HAND DEFORMITY 6297 0.7271
See all enriched reactions for Tumor Necrosis Factor Blocker [EPC]